179 related articles for article (PubMed ID: 34611179)
1. The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway.
Dong XL; Wang YH; Xu J; Zhang N
Sci Rep; 2021 Oct; 11(1):19737. PubMed ID: 34611179
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Li Q; Peng Y; Fan L; Xu H; He P; Cao S; Li J; Chen T; Ruan W; Chen G
Biomed Pharmacother; 2018 Mar; 99():947-955. PubMed ID: 29710495
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats.
Wan D; Zhou Y; Wang K; Hou Y; Hou R; Ye X
Brain Res Bull; 2016 Mar; 121():255-62. PubMed ID: 26876758
[TBL] [Abstract][Full Text] [Related]
4. Potent PDE4 inhibitor activates AMPK and Sirt1 to induce mitochondrial biogenesis.
Park SJ; Ahmad F; Bahde RJ; Philp A; Kim J; Huang T; Kim MK; Trenkle WC; Chung JH
PLoS One; 2021; 16(6):e0253269. PubMed ID: 34138962
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder.
Wang Z; Liang Y; Zhang L; Zhang N; Liu Q; Wang Z
Aging (Albany NY); 2018 Sep; 10(9):2394-2406. PubMed ID: 30227388
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
Schaal SM; Garg MS; Ghosh M; Lovera L; Lopez M; Patel M; Louro J; Patel S; Tuesta L; Chan WM; Pearse DD
PLoS One; 2012; 7(9):e43634. PubMed ID: 23028463
[TBL] [Abstract][Full Text] [Related]
7. PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
Kenk M; Thomas A; Lortie M; Dekemp R; Beanlands RS; Dasilva JN
Curr Radiopharm; 2011 Jan; 4(1):44-58. PubMed ID: 22191614
[TBL] [Abstract][Full Text] [Related]
8. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
Kraft P; Schwarz T; Göb E; Heydenreich N; Brede M; Meuth SG; Kleinschnitz C
Exp Neurol; 2013 Sep; 247():80-90. PubMed ID: 23570902
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 4 inhibitor rolipram improves survival of spiral ganglion neurons in vitro.
Kranz K; Warnecke A; Lenarz T; Durisin M; Scheper V
PLoS One; 2014; 9(3):e92157. PubMed ID: 24642701
[TBL] [Abstract][Full Text] [Related]
10. Rolipram Rescues Memory Consolidation Deficits Caused by Sleep Deprivation: Implication of the cAMP/PKA and cAMP/Epac Pathways.
Maher A; El Sayed N; Nafea H; Gad M
CNS Neurol Disord Drug Targets; 2022; 21(7):631-639. PubMed ID: 34397335
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
[TBL] [Abstract][Full Text] [Related]
12. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway.
Li D; Xu J; Qin Y; Cai N; Cheng Y; Wang H
Int Immunopharmacol; 2021 Jan; 90():107176. PubMed ID: 33243606
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.
Korhonen R; Hömmö T; Keränen T; Laavola M; Hämäläinen M; Vuolteenaho K; Lehtimäki L; Kankaanranta H; Moilanen E
Br J Pharmacol; 2013 Aug; 169(7):1525-36. PubMed ID: 23849041
[TBL] [Abstract][Full Text] [Related]
14. Selective enhancement of wnt4 expression by cyclic AMP-associated cooperation between rat central astrocytes and microglia.
Ohnishi M; Urasaki T; Ochiai H; Matsuoka K; Takeo S; Harada T; Ohsugi Y; Inoue A
Biochem Biophys Res Commun; 2015 Nov; 467(2):367-72. PubMed ID: 26431871
[TBL] [Abstract][Full Text] [Related]
15. Fear renewal activates cyclic adenosine monophosphate signaling in the dentate gyrus.
Shi YW; Fan BF; Xue L; Wang XG; Ou XL
Brain Behav; 2019 Aug; 9(8):e01280. PubMed ID: 31313894
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase-4 inhibition reduces ECLS-induced vascular permeability and improves microcirculation in a rodent model of extracorporeal resuscitation.
Wollborn J; Siemering S; Steiger C; Buerkle H; Goebel U; Schick MA
Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H751-H761. PubMed ID: 30681364
[TBL] [Abstract][Full Text] [Related]
17. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
18. Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK.
Park SJ; Ahmad F; Um JH; Brown AL; Xu X; Kang H; Ke H; Feng X; Ryall J; Philp A; Schenk S; Kim MK; Sartorelli V; Chung JH
EBioMedicine; 2017 Apr; 18():128-138. PubMed ID: 28396013
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
20. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
